Page last updated: 2024-08-26

bosentan anhydrous and act-132577

bosentan anhydrous has been researched along with act-132577 in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Binkert, C; Bolli, MH; Boss, C; Buchmann, S; Bur, D; Clozel, M; Fischli, W; Hess, P; Iglarz, M; Meyer, S; Rein, J; Rey, M; Treiber, A; Weller, T1
Bolli, MH; Boss, C; Gatfield, J1
Äänismaa, P; de Kanter, R; Delahaye, S; Hess, P; Sidharta, P; Treher, M; Treiber, A1
Alessandri, E; Brizzolara, R; Cutolo, M; Montagna, P; Pizzorni, C; Smith, V; Soldano, S; Sulli, A; Tavilla, PP; Villaggio, B1

Reviews

1 review(s) available for bosentan anhydrous and act-132577

ArticleYear
From bosentan (Tracleer®) to macitentan (Opsumit®): The medicinal chemistry perspective.
    Bioorganic & medicinal chemistry letters, 2016, 08-01, Volume: 26, Issue:15

    Topics: Bosentan; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Humans; Molecular Structure; Pyrimidines; Receptors, Endothelin; Structure-Activity Relationship; Sulfonamides

2016

Trials

1 trial(s) available for bosentan anhydrous and act-132577

ArticleYear
Macitentan does not interfere with hepatic bile salt transport.
    The Journal of pharmacology and experimental therapeutics, 2014, Volume: 350, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Bosentan; Cell Line; Cricetinae; Dogs; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Hepatocytes; Humans; Liver; Male; Organic Anion Transporters; Organic Anion Transporters, Sodium-Dependent; Pyrimidines; Rats; Sulfonamides; Symporters

2014

Other Studies

2 other study(ies) available for bosentan anhydrous and act-132577

ArticleYear
The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist.
    Journal of medicinal chemistry, 2012, Sep-13, Volume: 55, Issue:17

    Topics: Administration, Oral; Animals; Antihypertensive Agents; CHO Cells; Cricetinae; Cricetulus; Drug Discovery; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Pyrimidines; Rats; Rats, Inbred Dahl; Sulfonamides

2012
Effects of macitentan and its active metabolite on cultured human systemic sclerosis and control skin fibroblasts.
    The Journal of rheumatology, 2015, Volume: 42, Issue:3

    Topics: Actins; Aged; Bosentan; Down-Regulation; Endothelin A Receptor Antagonists; Female; Fibroblasts; Humans; Male; Middle Aged; Pyrimidines; Scleroderma, Systemic; Skin; Sulfonamides

2015